BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cohen EEW, Pishvaian MJ, Shepard DR, Wang D, Weiss J, Johnson ML, Chung CH, Chen Y, Huang B, Davis CB, Toffalorio F, Thall A, Powell SF. A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors. J Immunother Cancer 2019;7:342. [PMID: 31801624 DOI: 10.1186/s40425-019-0815-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Xie Y, Xie F, Zhang L, Zhou X, Huang J, Wang F, Jin J, Zhang L, Zeng L, Zhou F. Targeted Anti-Tumor Immunotherapy Using Tumor Infiltrating Cells. Adv Sci (Weinh) 2021;8:e2101672. [PMID: 34658167 DOI: 10.1002/advs.202101672] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
2 Salkeni MA, Shin JY, Gulley JL. Resistance to Immunotherapy: Mechanisms and Means for Overcoming. Adv Exp Med Biol 2021;1342:45-80. [PMID: 34972962 DOI: 10.1007/978-3-030-79308-1_2] [Reference Citation Analysis]
3 Ronen D, Bsoul A, Lotem M, Abedat S, Yarkoni M, Amir O, Asleh R. Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. Vaccines 2022;10:540. [DOI: 10.3390/vaccines10040540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chocarro L, Bocanegra A, Blanco E, Fernández-rubio L, Arasanz H, Echaide M, Garnica M, Ramos P, Piñeiro-hermida S, Vera R, Escors D, Kochan G. Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor. Cells 2022;11:2351. [DOI: 10.3390/cells11152351] [Reference Citation Analysis]
5 Zhang T, Sun J, Li J, Zhao Y, Zhang T, Yang R, Ma X. Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies. BMC Cancer 2021;21:618. [PMID: 34039310 DOI: 10.1186/s12885-021-08363-w] [Reference Citation Analysis]
6 Hong DS, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Front Immunol 2022;13:897991. [DOI: 10.3389/fimmu.2022.897991] [Reference Citation Analysis]
7 Nicolay JP, Albrecht JD, Alberti-Violetti S, Berti E. CCR4 in cutaneous T-cell lymphoma: Therapeutic targeting of a pathogenic driver. Eur J Immunol 2021;51:1660-71. [PMID: 33811642 DOI: 10.1002/eji.202049043] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Vogrig A, Muñiz-Castrillo S, Farina A, Honnorat J, Joubert B. How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update. J Neurol 2021. [PMID: 34708250 DOI: 10.1007/s00415-021-10870-6] [Reference Citation Analysis]
9 Kraehenbuehl L, Weng CH, Eghbali S, Wolchok JD, Merghoub T. Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol 2021. [PMID: 34580473 DOI: 10.1038/s41571-021-00552-7] [Reference Citation Analysis]
10 Lee DH. Update of early phase clinical trials in cancer immunotherapy. BMB Rep 2021;54:70-88. [DOI: 10.5483/bmbrep.2021.54.1.242] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Hashimoto K. CD137 as an Attractive T Cell Co-Stimulatory Target in the TNFRSF for Immuno-Oncology Drug Development. Cancers (Basel) 2021;13:2288. [PMID: 34064598 DOI: 10.3390/cancers13102288] [Reference Citation Analysis]
12 Korbecki J, Kojder K, Simińska D, Bohatyrewicz R, Gutowska I, Chlubek D, Baranowska-Bosiacka I. CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci 2020;21:E8412. [PMID: 33182504 DOI: 10.3390/ijms21218412] [Cited by in Crossref: 13] [Cited by in F6Publishing: 19] [Article Influence: 6.5] [Reference Citation Analysis]
13 Julian R, Savani M, Bauman JE. Immunotherapy Approaches in HPV-Associated Head and Neck Cancer. Cancers (Basel) 2021;13:5889. [PMID: 34884999 DOI: 10.3390/cancers13235889] [Reference Citation Analysis]
14 Matsuo K, Yoshie O, Nakayama T. Multifaceted Roles of Chemokines and Chemokine Receptors in Tumor Immunity. Cancers (Basel) 2021;13:6132. [PMID: 34885241 DOI: 10.3390/cancers13236132] [Reference Citation Analysis]
15 Cinier J, Hubert M, Besson L, Di Roio A, Rodriguez C, Lombardi V, Caux C, Ménétrier-Caux C. Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them? Cancers (Basel) 2021;13:1850. [PMID: 33924428 DOI: 10.3390/cancers13081850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Propper DJ, Balkwill FR. Harnessing cytokines and chemokines for cancer therapy. Nat Rev Clin Oncol 2022. [PMID: 34997230 DOI: 10.1038/s41571-021-00588-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 24.0] [Reference Citation Analysis]
17 Golay J, Andrea AE. Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. Antibodies (Basel) 2020;9:E17. [PMID: 32443877 DOI: 10.3390/antib9020017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Zhou Y, Penny HL, Kroenke MA, Bautista B, Hainline K, Chea LS, Parnes J, Mytych DT. Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology. J Immunother Cancer 2022;10:e004225. [PMID: 35444060 DOI: 10.1136/jitc-2021-004225] [Reference Citation Analysis]
19 De Giglio A, Di Federico A, Nuvola G, Deiana C, Gelsomino F. The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines). Curr Oncol Rep 2021;23:126. [PMID: 34453261 DOI: 10.1007/s11912-021-01124-9] [Reference Citation Analysis]
20 Ugolini A, Nuti M. CD137+ T-Cells: Protagonists of the Immunotherapy Revolution. Cancers (Basel) 2021;13:456. [PMID: 33530328 DOI: 10.3390/cancers13030456] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]